Sector News

Pharmaceutical research firm SynteractHCR explores sale: sources

April 13, 2016
Life sciences

SynteractHCR Inc, a privately held U.S. contract research organization (CRO), is exploring a sale that could value it at close to $1.5 billion, including debt, according to people familiar with the matter.

A deal would underscore how the CRO industry has benefited in recent years from pharmaceutical companies’ drive to cut costs, reduce clinical trial times and expand their research and development presence around the world.

SynteractHCR’s owner, private equity firm Gryphon Investors, is working with investment bank Wells Fargo & Co (WFC.N) to run an auction for the company, the people said this week.

SynteractHCR, based in Carlsbad, California, has annual earnings before interest, taxes, depreciation and amortization of aground $160 million, the people added, asking not to be identified because the sale process is confidential.

Gryphon Investors, based in San Francisco, and Wells Fargo declined to comment. SynteractHCR did not immediately respond to a request for comment.

SynteractHCR provides outsourced support to pharmaceutical companies, from drug development to marketing. It was created in its current form in 2008 when Gryphon Investors acquired majority ownership of the company and merged it with another company, Vince & Associates Clinical Research. It has since grown further through acquisitions.

The sale process comes as a string of other private equity-owned pharmaceutical services companies explore divesting themselves or initial public offerings. These include InVentiv Health Inc, eResearch Technology Inc and PCI Pharma Services.

By Carl O’Donnell

Spource: Reuters

comments closed

Related News

September 25, 2022

Rise of the machines: Novo Nordisk pledges $200M to create first quantum computer for life sciences

Life sciences

Big Pharma has long seen the potential for AI and machine learning to accelerate drug development. But Novo Nordisk is going a step further by channeling $200 million toward the creation of a computer that will outrun anything in existence.

September 25, 2022

Mount Sinai AI uncovers new brain analysis method to predict dementia, Alzheimer’s disease

Life sciences

Current methods for diagnosing Alzheimer’s disease rely on a complex combination of self- and caregiver-reported symptoms, a physical examination and either a PET scan or a spinal tap to look for evidence of amyloid plaque build-ups in the brain. But a new artificial intelligence-based method may make the diagnostic process a much more objective one.

September 25, 2022

New AstraZeneca-backed report finds big money behind diverse owners and entrepreneurs in Europe

Life sciences

There is lots of talk about diversity and inclusion in business, including in pharma and medtech. A new report by the Open Political Economy Network (OPEN), a think tank focusing on migration and diversity, released its “Minority Businesses Matter: Europe” report highlighting the successes and challenges of ethnic minority-owned businesses in Europe.